Abstract-Deep brain stimulation (DBS) therapy is a widely used brain surgery that can be applied for many neurological and psychiatric disorders. DBS is American Food and Drug Administration approved for medication refractory Parkinson's disease, essential tremor and dystonia. Although DBS has shown consistent success in many clinical trials, the therapy has limitations and there are wellrecognized complications. Thus, only carefully selected patients are ideal candidates for this surgery. Over the last two decades, there have been significant advances in clinical knowledge on DBS. In addition, the surgical techniques and technology related to DBS has been rapidly evolving. The goal of this review is to describe the current status of DBS in the context of movement disorders, outline the mechanisms of action for DBS in brief, discuss the standard surgical and imaging techniques, discuss the patient selection and clinical outcomes in each of the movement disorders, and finally, introduce the recent advancements from a clinical and technological perspective.
worldwide [6] , [7] . With these large numbers and growing popularity, the medical community has become more experienced and proficient in DBS techniques. At the same time, the patient population has become increasingly comfortable with the concept of a "bionic man."
A. DBS in Parkinson's Disease
Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease affecting 1-2% of persons over the age of 60 years [8] . The classical motor symptoms of Parkinson's disease are rest tremor, slowness of movements (bradykinesia), stiffness, shuffling of gait, and difficulties with balance, though not all need to be present for diagnosis [9] . The pathophysiological studies have uncovered abnormalities in basal ganglia circuits, which result in a characteristic change in rate and pattern of neuronal firing [10] , [11] . In one of the first observations made by E. Jefferson Browder, a neurosurgeon from England, Parkinson's disease symptoms were found to be improved when the caudate nucleus was accidentally extirpated [12] . In the late 1960s, when the pharmacological marvels of levodopa medication were discovered, enthusiasm for surgical therapies was noted to wane [11] . Levodopa therapy was the first pharmacological therapy for Parkinson's disease; it was noted to be an easy, effective, and potent therapy [13] . However, in the subsequent years, the adverse effects of these therapies such as motor fluctuations and dyskinesia became increasingly known. The clinicians learned that with oral levodopa therapy, there was only a window of optimal therapeutic benefit and motor fluctuations were recognized as a treatment challenge and a major limitation related to this therapy [14] . Although oral levodopa therapy continues to remain the cornerstone of Parkinson's disease treatment, given these limitations clinicians shifted their focus back to surgical therapies, such as thalamotomy, pallidotomy and subthalamotomy. However one major limitation with bilateral lesion surgeries was the development of numerous complications such as cognitive and speech issues also referred to as pseudobulbar symptoms. In 1987, A. Benabid from Grenoble, France, observed in one of his patients that although lesioning of thalamus [of the ventral intermediate (VIM) nucleus] on one side resulted in improvement of tremors, a high-frequency electrical stimulation delivered to the same target on the opposite side also resulted in similar tremor improvements [15] . This innovative treatment became popular very quickly as the electrical stimulation was reversible, programmable, and could be performed on both sides of the brain. This was the birth of chronic electrical stimulation for the brain, which is referred to as "DBS" [16] .
Currently, in addition to VIM nucleus in thalamus, DBS in Parkinson's disease is targeted to the subthalamic nucleus and globus pallidus interna for control of motor symptoms. Though DBS in Parkinson's disease has proven to be a powerful therapy for treatment of motor symptoms, there are significant potential adverse effects associated with this surgery particularly in speech, mood, and cognitive domains [17] - [19] .
B. DBS in Essential Tremor
DBS was first FDA approved for the treatment of essential tremor. In essential tremor, patients experience bilateral arm tremors that interfere with activities of daily living. Essential tremor is one of the most common movement disorders and is usually treated with oral medications. Approximately 50% of essential tremor patients do not improve with oral pharmacological medications [20] . Numerous bilateral DBS studies have shown arm tremors to improve by 60-80% even at a long-term follow-up at five years [5] , [21] .
C. DBS in Dystonia
In later years, DBS gained FDA approval for the treatment of dystonia. Dystonia is a disabling syndrome characterized by involuntary, sustained muscle co-contractions causing twisting movements and abnormal postures. Pharmacological therapies for primary generalized dystonia often show limited efficacy resulting in many patients developing a profound disability [22] . Anticholinergic medications, benzodiazepines, baclofen [23] and botulinum toxin injections are the first line treatment agents, however, lack of improvement or inadequate symptom relief are considered primary indications for surgery. DBS of the globus pallidus (GPi) has emerged as an effective treatment for medication refractory primary dystonia [4] . However, across studies, the clinical outcome with DBS has revealed a wide range of outcomes (43-76%) and in individual patients, these outcomes are poorly predictable [24] . DBS is more likely to be effective for mobile dystonia such as hyperkinetic dystonia, dystonic tremor, chorea, choreodystonia, and in some cases even myoclonus (e.g., the myoclonus dystonia syndrome). It is noteworthy that fixed aspects of dystonia and arthrosis secondary to dystonia do not seem to improve with DBS therapy. Many groups of clinicians and engineers are currently working to refine technologies and approaches to maximize the benefits and minimize the risks of DBS [25] .
D. DBS in Tourette Syndrome
In addition to the clinical success discussed in the aforementioned sections, DBS has been explored for many other conditions. In one such exploration in 1999, Vandewalle et al. experimentally targeted the ventral oral internus (Voi) and center median parafascicular (CMPf) nuclei of the thalamus as a treatment for Tourette syndrome [26] . Tourette syndrome is a movement disorder that presents in childhood and is characterized by multiple motor tics and vocal tics. In milder cases, psychobehavioral therapy such as relaxation training, cognitive behavioral intervention therapy (CBIT) and habit reversal training may be successful. In moderate cases, psychotropic medications such as α2-adrenergic agonists, typical and atypical neuroleptics, tetrabenazine, and benzodiazepines are used. In a small subset of patients who have self-injurious potentially lifethreatening tics ("malignant TS"), DBS may be an option and initial results are promising and encouraging [27] . DBS seems to help motor and vocal tics more than behavioral manifestations, but more research will be needed. The main underlying theory proposed for Tourette syndrome is that there is an increased excitation of the frontal cortex and a decreased inhibition of the thalamus. The targets in the thalamus are presumed to act as important nodes in the limbic circuitry running through the frontal associative cortex, striatum, and the thalamus. Dysfunction in these two areas is hypothesized to result in a failure to suppress an abnormal motor program or a behavioral outburst.
II. MECHANISMS OF ACTION FOR DBS
DBS involves implantation of specialized leads into specific targets within the brain. The general concept underpinning the therapy is that there are nodes within the brain circuits where many pathways converge or pass critical information, and electrical stimulation of these nodes can "neuromodulate" these circuits. These electrical effects on complex neural networks are thought to ultimately improve the clinical symptoms [2] . Even though DBS has shown tremendous clinical success, surprisingly, the exact mechanism of action is still not clear. Scientists have been puzzled by the effects of DBS, and they believe the DBS effects are mediated through a multitude of pathways at multiple levels [28] . The electrical field of DBS inhibits the neuronal cells that are close to the electrode, at the same, it excites the axonal fibers that are traversing the field of activation. DBS preferentially stimulates the large axons. In addition to electrical effects, DBS has chemical and biological effects. The electrical current delivered to the neuronal synapse triggers the astrocytes in the immediate neighborhood of the electricity to release a wave of calcium and as a result release neurotransmitters (e.g., adenosine and glutamate) [29] , [30] . DBS has been observed to stimulate blood flow in the field of activation. Although DBS modulates the neuronal firing pattern of the activated neuronal cells and the brain network [2] , chronic stimulation induces effects in the upstream and downstream networks [31] . Interestingly, the changes in neuronal oscillations are found to correlate with many of the improvements manifested during therapy. In a nutshell, despite gaining extensive knowledge on the biological changes associated with DBS therapy, we have yet to pin down the effects most relevant to its mechanism of action.
III. SURGICAL METHODS: STANDARD TECHNIQUES AND NOVEL TECHNIQUES
Since their introduction, surgical techniques for DBS have continued to evolve. DBS centers often have differences of opinion in their surgical approach with no consensus guidelines yet established on the optimal approach. Neurosurgeons select their technique(s) depending on their training and work related experience, the hardware and scanners available to them, and the capabilities of staff and facilities. Several stereotactic frames are now available for commercial marketing including the Leksell (Elekta AB, Stockholm, Sweden) or Cosman-Roberts-Wells (CRW; Integra Radionics, Burlington, MA, USA), RiechertMundinger frame, and others [32] .
One technique commonly used is CT-MRI fusion. In this technique, on the day of surgery, the stereotactic frame is applied to the patient's head [33] . Although these frames are heavy and may cause discomfort, they stabilize the head and serve as fixed points of reference for accurate brain targeting. MRI is performed prior to the day of surgery and the computed tomography (CT) is obtained on the day of the surgery with the stereotactic frame attached to the head. The MRI and CT images are coregistered with the fiducial points on the metallic frame. The final brain target is achieved with indirect (coordinate system), and then, with direct targeting (the neurosurgeon visualizes the target and adjusts the approach to the image). In the past, a coordinate system derived from a cadaveric brain atlas was employed for targeting, and this has been referred to in the literature as indirect targeting. However, indirect targeting is prone to errors, thus this practice has become less preferred. There are other intra-operative techniques that can be utilized beyond CT-MRI fusion (e.g. direct MRI, frameless, others).
Most DBS centers rely on neuroimaging techniques for direct targeting such as CT or MRI for direct targeting in conjunction with indirect targeting to accomplish an accurate selection of the brain target and planning of a safe trajectory [34] , [35] . Ventriculography is an invasive procedure, and thus, rarely used. MRI has an excellent tissue resolution allowing direct visualization of brain structures including the subthalamic nucleus, however due to warping, it is prone to errors for detection of external fiducials. A standard T1 weighted MRI sequence can be used for identification of the globus pallidus internus and T2 weighted imaging may improve the contrast between the STN, SNr, red nucleus (RN), and pallidum. At our center, we found, the specialized Fast Gray Matter Acquisition T1 Inversion Recovery (FGATIR) 3T MRI sequence more reliable in better delineation of the globus pallidum and subthalamic nucleus borders [36] . In these specialized sequences, the subthalamic nucleus along with the red nucleus is hypointense relative to the surrounding area. Each possible MRI scanning sequence for targeting has positives and negatives and in general most centers use individual preference to choose the MRI sequence.
For the thalamus with the currently available MRI sequences, it is not possible to delineate the thalamic subnuclei including the ventral intermedius nucleus targeted for essential tremor and there may be a future role for fMRI or other advanced imaging. Once the MRI is performed with appropriate sequences (see Fig. 1) , MRI images are then fused with the CT images, which are easily achieved with modern image-guided systems. These fusion methods increase the accuracy of targeting; however, one study cited an error in the range of 1.3-mm error can arise in this process. Many DBS centers thus complement the Fig. 1 . A) DBS implantation into globus pallidus interna. The optimal location for DBS lead is in the postero-ventro-lateral part of nucleus. If the lead is too medial it will stimulate the internal capsule and if too lateral it will be outside the target. Mapping of coordinates on high resolution MRI sequences is guided by the standard cadaver derived atlas of anatomical structures and by targeting. B) DBS implantation into the ventral intermedius nucleus of the thalamus. The optimal location for the DBS lead is approximately 2-mm anterior to the border of ventralis caudalis nucleus, but this is highly patient and trajectory specific.
imaged-based targeting with microelectrode recording (MER) techniques (discussed later) [32] .
Once the imaging-derived coordinates are entered into stereotactic arc system, the skin is prepared and a burr hole is created at the entry point of the trajectory. The stereotactic frames mounted to the patient's head and affixed to the operating table to serve as a fiducial system to translate the coordinates for the brain target determined on the computer at the workstation (image space) into their physical space. The microelectrode system (if used) is then mounted for recording of the target area. MER encompasses a physiological mapping for final refinement of the target location in the brain. A thin, fine, high-impedance electrode (though choice of electrode is center dependent) is introduced through a single-pass or multiple-pass cannula to reach the target area. During this process, characteristic sounds generated by the neuronal firing are identified and the waveforms are examined in real time. The anatomical location of the targeted brain area and the surrounding brain structures are delineated, and the gaps between the structures are noted. Although MER penetration is useful for final inference on the lead position, there is an inherent risk of bleeding especially if patients have hypertension [37] . According to one metaanalysis, MER techniques are five times more likely to develop brain hemorrhage, though there is considerable debate on this topic [38] . Gorgulho et al. founded a slightly higher incidence of hemorrhage in MER-guided DBS (2.9% of patients undergoing MER versus 1.4% without MER), but in this study it was not statistically significant [39] . Haim et al. suggested that with newer microelectrode designs, the number of hemorrhages have been found to significantly decrease [40] . Age, hypertension, and number of MER tracks are factors that contribute further to the bleeding risk [41] .
There are two models of DBS leads manufactured by the Medtronic Company [(Minneapolis, MN, USA) see Fig. 2 ]. The 3 387 lead contains four 1.5-mm cylindrical electrodes separated by 1.5-mm insulation. The entire span of contacts is 10.5-mm long. The second 3 389 model also has four 1.5-mm cylindrical electrodes but the 0.5-mm intercontact insulated interval reduces the entire span of contacts to 7.5-mm length. As a result, the spatial resolution of this lead may be more optimal particularly, when targeting the smaller brain regions like ventral intermedius nucleus and subthalamic nucleus, though the choice is surgeon dependent. Some DBS centers prefer the longer lead with larger 1.5-mm spaces even for smaller brain targets to compensate for suboptimally placed leads or lead migration. There are other companies, such as St. Jude and Boston Scientific, who are entering the U.S. market with different lead configurations.
Once the DBS lead is placed, some centers use intra-operative fluoroscopy to avoid migration. The lead is locked in place by a securing device or other technique. There are other methods that include the Stim-Loc cranial base and cap, titanium plates, methyl-methacrylate or bone cement in combination with a nonabsorbable ligature. DBS centers using bone cement in combination with a ligature have observed very few issues with lead migration.
The DBS lead is connected with the neurostimulator placed in the chest wall with the help of a lead extension cable. Since the DBS hardware is bulky and placed mostly in the subcutaneous plane, skin erosion can occur particularly over the burr hole site on the scalp; the site where the lead extension connects to the DBS lead and erosion can also occur in the chest wall skin over the neurostimulator. In some DBS centers, a lead-cap counter sink is created at the site of the burr hole so the protrusion above the scalp is minimized. The lead extension may also be placed in a trough that is drilled into the parietal skull region. Although, titanium plates and the stim-loc cap may have fewer migration related complications than the Medtronic cap, there is a possibility of skin erosion with excessive pressure on the DBS lead [1] .
In parallel with the clinical successes of DBS, engineers have also been constantly working toward improving the DBS technology. These changes have been evolving in virtually every aspect of DBS, whether related to preoperative identification of a brain target, intraoperative surgical technique, novel lead design configuration, stimulation patterns, or improved methods for postoperative programming.
A. Frameless DBS and MRI-Guided DBS
In recent years, frameless DBS techniques have gained enthusiasm mainly because of alleviation of the discomfort arising from the traditional stereotactic frames that are heavy and may be less tolerated by children, patients with painful cervical dystonia and when the surgeries require a long time for completion. Another important advantage is easier access to the airway should an emergency situation occur, although most frames are equipped to allow for intubation. In 2001, the microTargeting platform (MTP) stereotaxy system (FHC Inc., USA) was FDA approved and offered platforms to meet the needs of individual stereotactic procedures. In this procedure, patients are seen in person a few days ahead of a surgery date for fixation of bone fiducials (usually under local anesthesia). The term "fiducial" refers to markers inserted to provide a frame of reference for use during targeting. The scalp is shaved and bone anchors are screwed into the skull with aseptic precautions. Typically, the same day, the patient also has an MRI of the brain performed preferably under anesthesia. This approach is especially helpful in patients who are claustrophobic, and for those patients who cannot remain still due to tremors and dyskinesia or if a patient has cervical dystonia. Motion-free images are likely to improve the quality of trajectory planning. Using the Schaltenbrand and Wahren Atlas (or an equivalent atlas), coordinates for targets are selected on the MRI images using direct targeting techniques [42] , [43] . After the target is identified and the trajectory is planned, specialized software is employed to design a customized MTP [44] . Although this approach of using customized MTPs reduces the operation time by approximately 2 h, it adds to the risk associated with general anesthesia and adds an extra planning day. The results obtained with frameless DBS in clinical studies have been found to be comparable to those with frame-based DBS. There have been drawbacks related to the frameless system. The system is nonreusable, adds substantially to the cost, the system is plastic and lightweight and thus less securely fixed compared to the standard metallic frames. Frameless technology also involves an additional procedure for the placement and removal of fiducial markers from the skull, which adds a potential infection risk.
MRI-guided DBS has emerged as an alternative consideration to mitigate risks associated with the MER technique used for standard DBS procedures and to potentially allow patients to be asleep. In MRI-guided DBS, patients receive general anesthesia and undergo surgery in a dedicated MRI suite. MRI performed intraoperatively has the advantage of allowing a real-time determination of target location and the final electrode position. If there are concerns for brain shift or if a complication of intraparenchymal hemorrhage arises, a real-time monitoring procedure facilitates adjustment of the electrode. Intraoperative MRI does not allow specific macrostimulation-based refinement of electrode position as the patients are under anesthesia, and this could lead to suboptimal lead placement. Many small-scale clinical studies have shown significant improvements in clinical scores, as well as in the quality of life outcomes. Whether using intraoperative MRI has better outcomes compared to a standard technique will require systematic investigation in a large clinical study.
The accuracy of electrode placement has been confirmed with postoperative MRI, which reveals the mean error of displacement is approximately 1.3 mm with MRI (in one study), however, placement of a DBS lead cannot be judged on imaging alone [45] . The thresholds for benefits and side effects and the clinical response to therapy are actually more important than the physical image. Though these findings are encouraging, the progress of MRI-based techniques is currently hampered by the limitations in real-time lead adjustment; a lack of intraoperative clinical testing for a DBS lead, the procedure requires anesthesia and sometimes it may be difficult to accurately visualize the subthalamic nucleus. Additionally, patients undergoing MRI-based procedures should have detailed testing in the clinic to confirm accurate placement of the lead and in some cases patients may need to return to the operating room for an adjustment.
IV. GUIDELINES FOR DBS PROGRAMMING
DBS lead implantation often results in immediate benefits even without electrical activation and these effects have been largely attributed to microlesion effects. These effects presumably arise from trauma induced by the placement of a DBS lead in the brain target, and are not related to therapeutic stimulation of the target. DBS programming in movement disorders is not usually started until about 2-4 weeks of time has elapsed since the placement of electrode, thus allowing an adequate wash-out time for the microlesion effects to disappear. Interestingly in some cases, these effects may be persistent and account for some of the benefits.
DBS programming performed at the bedside can be accomplished by a health care provider who has adequate training, experience, and expertise. For a successful programming session, it is important to be aware of the DBS lead type and the configuration. Lead configuration refers to the size of the contacts and the distance between each of the DBS contacts. At our center, a postoperative CT brain is performed and it is coregistered with a preoperative MRI scan to confirm lead location and specifications of the lead configuration. In December 2015, the FDA approved full body MRI scan for select Medtronic DBS systems, which now allows MRI of other body regions under strict conditions. This advance will facilitate imaging of other body parts particularly for unrelated conditions (e.g. spine issues, or torn ligaments in a knee).
DBS centers with intraoperative MRI allow for immediate confirmation of lead location, though edema and pneumocephalus may cloud interpretation in some cases. Once the programmer is turned ON, the first step is to record the electrical impedance at each of the contacts to verify the intactness of the electrical system. If impedances are excessively below the normal range, it indicates a short circuit, whereas if the impedances are above the normal range, it indicates an open circuit.
The success of DBS programming is driven by many factors including the underlying nature of disease, placement of the lead in optimal location, the stimulation parameters chosen, and the individual based demographic characteristics. DBS activates large myelinated fibers before small axons or cell bodies, it tends to activate axons near the cathode instead of the anode, and has a preference to stimulate the axonsoriented parallel to the electrode rather than those oriented transversely [46] , [47] .
Many principles of DBS programming remain common across various indications. We will first discuss the general guidelines and in subsequent sections provide important highlights related to programming in essential tremor, Parkinson's disease, dystonia, and Tourette syndrome. It is important to keep in mind that there are no universally accepted guidelines for DBS management, thus most of the management has been guided by empirical approaches and expert opinion. As a general rule, each DBS contact is individually stimulated and tested. Each electrode contact is initially stimulated with a monopolar configuration (electrode contact is negative and neurostimulator case is positive). Stimulation settings for each of the three parameters pulsewidth, frequency, and voltage may vary according to the needs and response of the underlying condition. For example, a pulsewidth of 60-90 μs and frequency of 130-160 Hz is chosen for essential tremor, whereas higher pulsewidths and sometimes lower frequencies (60 Hz) are found to be effective in dystonia. The voltage at each contact is titrated with increasing increments of 0.1-0.5 V until benefits are elicited (at lower voltage) and adverse effects (at higher voltage) are documented. The benefit to adverse effect ratio at each contact is referred to as a "threshold" by DBS programmers. During threshold testing often the pulsewidth and rate are held steady, while the amplitude (voltage) is slowly raised. The difference between the benefit to side-effect voltages establishes the therapeutic window for that contact. In a wellpositioned DBS lead, the voltages required for clinical benefits are well below the thresholds for subjective and objective adverse effects [48] . The electrode contact that has the largest therapeutic window is usually selected for chronic stimulation. If stimulation of single contact with monopolar configuration is not satisfactory, double monopolar stimulation is employed (a negative polarity is assigned to the two contacts that are selected and positive polarity is assigned to the neurostimulator case). Although monopolar stimulation usually requires lower voltages for clinical benefits, if low-voltage levels are observed to induce stimulation-induced side effects, the next appropriate step is to proceed with a bipolar configuration. With a bipolar configuration, the electrode contact with optimal therapeutic threshold as observed in a previous monopolar evaluation is set at a negative polarity and the adjacent contact is set at a positive polarity. Finally, if the clinical symptoms are not controlled due to stimulation-related side effects, even after considering alternate stimulation parameters, repositioning of the DBS lead may be considered [49] , [50] . DBS programming is typically scheduled every month for the first six months and then is scheduled on an as-needed basis. Annual follow-up is scheduled to keep track of clinical response, check battery performance, and to troubleshoot if any adverse events are noted. Once the optimal settings are discovered on the DBS device, there will be only minor changes in programming during chronic management. Many practitioners and patients erroneously believe that the DBS device is designed to be "tweaked" at every follow-up visit, but this can potentially lead to a suboptimal outcome. There are many approaches to programming DBS devices and the above details only one common approach.
A. DBS Programming in Essential Tremor
In essential tremor, clinical studies with a longer follow-up have observed that the average voltage for stimulation is 2.4-4.4 V, the average frequency is 143-173 Hz, and the average pulse width is 67-138 μs [51] . There is immediate suppression of tremor in most essential tremor patients, and the DBS device is often turned off during the night while the patients are asleep (to conserve battery life). As far as the need to continue preoperative oral pharmacological agents is concerned, it is individually based but in many cases it is possible to discontinue pharmacological therapies. We retrospectively analyzed our essential tremor patients (n = 69) who had been followed for at least three years after undergoing VIM DBS. We found about 40% of unilateral VIM DBS patients continued their oral medications in conjunction with DBS therapy, whereas the medication requirement was usually completely eliminated in most bilateral VIM DBS patients [52] . One myth of essential tremor DBS is that it always relieves 100% of the tremor and it also treats the clumsiness associated with the disease. Also an important difference between the tremor of essential tremor and Parkinson's disease, is that the essential tremor continues to progress despite the DBS therapy [53] , whereas the Parkinson's disease tremor stays largely for the life of the device.
B. DBS Programming in Parkinson's Disease
DBS programming in Parkinson's disease follows similar expert guidelines as are followed in essential tremor. There are microlesion effects that tend to wear off in 2-4 weeks after implantation. There are also important differences with regards to the timing of programming. We prefer to perform programming in the morning as patients are required to come off their dopaminergic medications the night before the programming session, in order to elucidate true stimulation induced responses and separate them from medication responses. If patients are unable to present to the outpatient clinic because they cannot tolerate the off-medication state, or if there are no family members to bring them, an inpatient programming session is conducted at some centers. An alternate approach is to allow the patients to take their medications in the early morning before they present to the clinic, and to begin programming once the patients begin to experience a clinical off (wearing off their dopaminergic medications). Similar to essential tremor, tremors in Parkinson's disease usually respond immediately upon turning ON the stimulator. In addition to the tremors, rigidity also responds quickly, however, bradykinesia tends to respond more slowly. The effects of DBS on levodopa-induced dyskinesia are examined once the patients are administered their typical dopaminergic doses. Sometimes cumulative effects of two or three levodopa doses are needed before clinical dyskinesias are evident. A word of caution during programming is to keep in mind that sometimes dyskinesia are stimulation induced and not medication induced. This phenomenon is more common in subthalamic nucleus than globus pallidus internus DBS. The optimum electrode combination in globus pallidus internus DBS cases is to select a balanced configuration that improves off-medication parkinsonism without inducing stimulation induced dyskinesia and to control on-medication dyskinesia without worsening on-medication parkinsonism. Similarly, in subthalamic nucleus DBS cases, confusion can arise when dyskinesia are related to stimulation and not truly related to the dopaminergic medications. In these cases, voltages may need to be increased very slowly over time. The optimal settings in most circumstances are 60-90 μs for subthalamic nucleus and 90-120 μs for globus pallidus internus, and the frequency settings are 130-160 Hz [48] .
DBS programming is usually focused on one body side at a time (contralateral benefits), although one should also watch out for ipsilateral benefits of the stimulation. The optimal parameters are usually achieved three to six months after surgery. In cases with subthalamic nucleus DBS, as the programming parameters become established dopaminergic medication doses are gradually reduced. Though medications can be reduced with globus pallidus internus DBS, they are usually not reduced as much as in subthalamic nucleus DBS. Finally, there is a phenomenon called brittle dyskinesia, in which small dosages of medication lead to severe dyskinesia and these cases can be difficult to manage with subthalamic DBS. In some cases, patients have been converted to globus pallidus internus DBS. Globus pallidus DBS seems to have more of a dyskinesia suppressor effect, and in subthalamic DBS, dyskinesia is better controlled by medication reduction, which may not be possible depending on the disease state of an individual [54] , [55] .
C. DBS Programming in Dystonia
Dystonia patients undergoing DBS do not commonly experience a "honeymoon period" related to the microlesion effects, similar to what is seen in essential tremor and Parkinson's disease. Unlike Parkinson's disease, dystonia patients are also not asked to withhold the medications during programming as they cannot tolerate the discomfort arising from dystonic symptoms and the medications typically do not have a profound effect on the symptoms.
The initial contact for stimulation in most circumstances is usually one of the deepest contacts located in the ventral region of the globus pallidus internus just above the optic tract. Based on the data available from primate studies, the sensorimotor territory of the globus pallidus internus is the ventral and posterior region. Stimulation of this region has been observed to control dyskinesia in many patients [56] . Following several trial and error empirical programming settings, the most frequently chosen contacts for stimulation in dystonia are contacts 1 and 2 with some patients requiring a double monopolar configuration. Occasionally, a tetrapolar stimulation (all four contacts on the lead negative) is found to be effective indicating the need for a larger volume of tissue activation, but in these cases, there may also be a suboptimal lead placement. Some DBS centers prefer to use the Medtronic model 3387 lead that has larger distance between contacts to capture a much larger globus pallidus internus volume and to hopefully enhance the effect when using multiple contacts.
Programming for dystonia patients can be clinically challenging. Acute stimulation often has no effect on symptoms, and thus, a more chronic stimulation for a week or more is pursued. Sometimes alleviation of anxiety and tension is reported by the patients in the acute setting and this may guide the programmer in choosing the optimal contact. Higher stimulation voltages, and pulse widths are usually required for control of dystonia as compared to control of tremor or Parkinson's disease. As for the frequency parameter, some DBS centers including ours have observed that lower frequencies in the range of 60-90 Hz may be effective. The pulsewidths used in these cases tended to be longer and in the range of 180-220 μs to facilitate stimulation of larger neural elements, though more research is needed to confirm why a wider pulsewidth seems to be more effective [28] .
Neurostimulator batteries in dystonia may need to be changed every 12-18 months or whenever high stimulation settings are needed [57] . In cases where low voltages settings are used, the battery life may be considerably better. Considering a lifelong commitment needed in dystonia children undergoing DBS, rechargeable batteries are a reasonable alternative. In a large series of patients, lead location was found to be probably more important than the stimulation settings for DBS outcomes in dystonia [58] . Unlike essential tremor and Parkinson's disease, dystonia tends to improve slowly with DBS; sometimes the benefits are not seen for 6-12 months of follow-up after the surgery. Thus patients need to be properly educated to persist with programming trials, especially if the lead is verified to be well positioned. Medication dosages are tapered or completely stopped in some cases, once the DBS benefits appear [24] .
D. DBS Programming in Tourette Syndrome
DBS experience in Tourette syndrome is still growing and the lessons from programming continue to evolve. Comorbidities such as anxiety disorder and obsessive-compulsive disorder play an important contributing factor in the overall outcome of Tourette DBS, and should be given careful consideration. There is significant variation in the targets chosen for Tourette syndrome, and the amount of current delivered across individuals and even between brain sides of the same individual. The time course of clinical outcomes also shows a wide range among published studies. There is no expert consensus on programming guidelines [59] . Programming for Tourette syndrome may be frustrating as the frequency of motor tics tends to improve more gradually than is seen in tremor and Parkinson's disease and there may be fewer bedside hints for determination of proper settings. The Tourette Syndrome Association of America is assembling an International Database to address targeting and programming related issues [27] .
V. PATIENT-RELATED CHARACTERISTICS

A. Selection Process for the Optimal Surgical Candidate
In order to accomplish optimal clinical outcome, candidates for DBS should be selected only if they have been carefully evaluated. Proper selection of surgical candidates can potentially avoid many DBS failures [49] . DBS candidacy in Parkinson's disease is determined based on many factors such as the age, disease duration, response to levodopa, and the comorbidities [60] . Although many believe a younger age, a shorter disease duration and the absence of comorbidities seem to predict a better outcome, in one study [61] , these factors did not uncover any specific advantage. Similarly, a response to the levodopa therapy has also been regarded as a predictive factor for a positive surgical outcome. Levodopa response refers to a 30% reduction in the clinical motor score when a suprathreshold levodopa dose is administered to Parkinson's disease patients who have remained off of their medications for at least 12 h [62] . However, at our center, we observed, specific Parkinson's disease symptoms such as tremors or levodopa induced dyskinesia improved with DBS even though preoperatively some patients did not respond to levodopa at the 30% threshold [63] . Most Parkinson's disease patients are treated with pharmacotherapy, and only 10-20% of Parkinson's disease patients are good candidates for the traditional DBS surgery [64] . This number is expected to change with the recent enthusiasm to offer DBS earlier in the course of disease in patients with Parkinson's disease and this approach has been linked to a better quality of life. In this recent study, patients with earlier onset Parkinson's disease and motor fluctuations for only two years or less had a superior clinical outcome as compared to a medical control group [64] .
The selection process for a DBS candidate involves evaluation by multiple disciplines to avoid potential psychiatric and cognitive complications and to avoid complications related to worsening balance and speech. Thus, potential candidates for DBS surgery are ideally screened by an interdisciplinary team including neurology, neurosurgery, psychiatry, and neuropsychology. The team optimized medical therapy and develops a complete risk-benefit profile for discussion between the patient and family and the DBS board. DBS of the subthalamic nucleus has been found to induce hypomania in 4-15% of cases [65] , [66] , and postoperative depression in 1.5-25% of patients [67] . Some studies have also raised concerns for suicide attempts and/or suicides in subthalamic nucleus DBS surgery. In one large international multicenter survey of about 5000 Parkinson's disease patients undergoing subthalamic nucleus DBS surgery, an increased risk of attempted and completed suicide was found in the first year after surgery. Excessive impulsiveness, previous history of a suicide attempt, and a younger age of onset for depression contributed toward attempted suicides, whereas an emergence of postoperative depression played an important role in completed suicide [68] . Investigators also found an increased likelihood of suicidal ideation and behavior correlated with a significant reduction in dopaminergic medication dose after DBS surgery. However, in another study by Weintraub et al., an increased risk was not observed when close clinical follow-up was performed on Parkinson's disease patients enrolled in a multicenter DBS study, which likely was attributed to smaller reduction of dopaminergic medication dose [69] .
In addition to the psychiatry evaluation, a neuropsychological evaluation is helpful as cognitive issues such as a decline in word fluency can emerge after DBS. In some centers, rehabilitation disciplines such as physical therapists, occupational therapists, and speech therapists are considered standard of practice for screening DBS patients. Each of these disciplines after evaluating a patient, meet together either on a weekly or a monthly basis to discuss the risks, benefits, and care strategies. During these meetings, they may review the video examination of a potential candidate for affirmation of clinical features and give due consideration to the comorbidities, medical imaging studies, and patient expectations. Eventually every candidate's risk-benefit profile and expectations from surgery whether reasonable and achievable are discussed [7] , [70] . Once the interdisciplinary meeting is completed, a final decision on surgery is communicated to patients and families. If an individual does not clear the interdisciplinary evaluation, red flags for the surgery are addressed before a potential second evaluation.
Similar to Parkinson's disease, essential tremor and dystonia patients undergo an extensive interdisciplinary evaluation. Patients are selected for DBS only if the tremors or dystonia are severe, disabling, interfere with activities of daily living, and are refractory to pharmacological medications. Tourette syndrome has emerged as one of the latest indications for DBS and there is also a similar selection process.
VI. CLINICAL OUTCOMES WITH DBS
A. Parkinson's Disease
After the initial success of DBS therapy in several openlabeled and uncontrolled Parkinson's disease studies, DBS was examined in many large scale international multicenter clinical trials. These trials included the large Veteran administration cooperative multicenter program study in United States [3] , the Quality of Life Study initiated in Germany [50] , the UK PD Surge Trial [71] , and the NSTAPS study from Netherlands [72] . These trials have shown that DBS performs better than medical therapy in specific situations. DBS controls motor fluctuations, which mainly refers to worsening of motor symptoms when oral levodopa wears off before the next dose or alternately when there is emergence of excessive bothersome involuntary movements (dyskinesia). DBS therapy results in a significant increase in the quality "on time," a decrease in the overall "off time," and there is alleviation of levodopa induced dyskinesia. On an average, there is a 50-80% improvement in dyskinesia and about a 50% reduction in "off time," though this can be highly variable across individual patients. Another indication for DBS is severe tremors related to Parkinson's disease that are medication refractory. DBS of the VIM nucleus in the thalamus has been shown to ameliorate tremors with confirmation of persistent benefits at long-term follow up of 6 years [73] . The VIM target is, however, not frequently used in Parkinson's because it does not address other features such as bradykinesia and rigidity [73] and at the same time, the subthalamic nucleus and globus pallidus have also proven to be effective targets for tremor supression.
For many years, most DBS centers worldwide preferred subthalamic nucleus as the brain target for Parkinson's disease symptoms. Alternate targets such as the globus pallidus internus were not given due consideration until a systematic comparison was conducted. There have been at least three large randomized controlled blinded studies that have compared the efficacy of targeting the subthalamic nucleus versus the globus pallidus internus [70] , [74] , [75] . These studies have demonstrated similar motor improvements with subthalamic nucleus and globus pallidus when comparing motor outcomes. The Veterans Administration Cooperative Study enrolled 147 patients to receive subthalamic nucleus DBS and 152 patients to receive globus pallidus internus DBS and found the motor improvements at two years follow-up were equivalent with both targets [75] . Concerns were raised that the benefits with globus pallidus DBS were temporary, however, when these patients were followed clinically for another one year, it was observed that the benefits in both arms were sustained [76] . However, the rate of cognitive decline was greater in the subthalamic nucleus group. In another randomized NIH sponsored study (COMPARE trial), unilateral subthalamic nucleus DBS when compared with unilateral globus pallidus DBS resulted in equivalent motor benefits at seven months of follow up, though the subthalamic nucleus group had a greater decline in verbal fluency. The NSTAPS study from Netherlands included a composite outcome of cognition, mood, and behavioral effects instead of traditional motor scores and quality of life. These authors also found improvements that were comparable across both targets and there were no differences in the risk for side effects. Thus, selection of subthalamic nucleus versus globus pallidus internus as the treatment target should not be based solely on motor function but should be tailored to individual symptom and risk profile.
The St. Jude trial was conducted in Parkinson's disease patients to determine if a novel constant-current device was better than a voltage-controlled device. A constant-current device has an advantage of keeping the current delivered stable despite heterogeneous tissue impedances. In this trial, the motor scores at one year improved by about 40% even when the patients were examined "off" medications, and the time spent as feeling "on" was improved by 4 h when compared to baseline. These findings were consistent with other studies that employed voltage-controlled devices [77] . It is likely, considering the more consistent current delivery, that constant-current device will be used for future devices, though this is speculative.
Another important consideration for patients undergoing DBS is whether they will require unilateral or bilateral implantation of leads. Bilateral DBS in Parkinson's disease has been associated with increased complications such as worsening of speech, mood, and cognition. In the COMPARE trial, motor benefits sustained at 3.5 years follow up were observed on the ipsilateral side of the body and these remained sustained at 3.5 years follow-up [74] . Bilateral DBS was required in cases with higher preoperative motor disease and more symmetrical symptom pattern [78] . Some centers also advocate staging, in which unilateral lead implantation is followed by the second side DBS once optimization with the first device is achieved and the risks, benefits, and expectations from contralateral DBS are discussed.
Traditionally, DBS therapy is offered when the patients are about many years into the disease course or about 5 or more years after the diagnosis. This time frame is a relevant consideration as Parkinson's disease patients experience bothersome dyskinesia or motor fluctuations during this time and waiting 5-7 years makes it less likely that there was an underlying atypical Parkinsonism. There is now growing enthusiasm for offering DBS intervention earlier. The rationale for early DBS is underpinned by the potential for improved activities of daily living, social status, and possibility of occupational gain considering the early alleviation of motor disability. If DBS is delayed and performed in older patients and more advanced disease, the likelihood of surgical complications is higher and the ongoing difficulties in social relations with spouses and families will be less likely to resolve. In a recently concluded randomized controlled study of 251 Parkinson's disease patients, DBS was performed when the average disease duration was 7.5 years and the average duration for motor fluctuations was less than two years. The study found robust improvements in the quality of life assessment, and there were fewer DBS-related adverse effects than expected. These results were probably related to the younger age of the cohort, however, replication of benefits in older Parkinson's disease patients remains to be confirmed [79] . Some investigators have proposed DBS intervention even earlier (at less than five years into the disease) and even before the onset of motor fluctuations, however, this approach has been considered less compelling and riskier, until more data are gathered [80] . Early in the presentation, the diagnosis of Parkinson's disease is tricky, and as indicated earlier, some patients may evolve into other Parkinsonian conditions such as the atypical parkinsonism. A surgical intervention at an early stage may expose a patient to unnecessary procedural risks particularly when the long-term benefits of DBS in these cases are not clear. These factors should be taken into careful consideration.
B. Essential Tremor
DBS in essential tremor targeted toward the VIM nucleus thalamus successfully controls arm tremors with a complete initial remission in some patients [53] . DBS improves the contralateral arm tremor by about 60-80% even at long-term follow-up (10-15 years after the surgery) [81] . Some experts believe that the positive DBS effects are likely related to the targeting of the dentate-rubro-thalamic tract and intervention in the cerebellothalamo-cortical loop [82] . Once the DBS lead is implanted (and not activated), the tremor can be improved in many patients even without activation, which is referred to as the microthalamotomy or lesion benefit. These benefits like a "honeymoon effect," they characteristically fade away over the weeks following the surgery. DBS in essential tremor has been shown by multiple studies to be safe. In a questionnaire-based study conducted 6-16 years after surgery, the DBS procedure was found to be well tolerated and safe with no increase in mortality [83] . An important concern raised frequently in the literature relates to developing tolerance to DBS. A large retrospective analysis, showed that the reduced benefits with DBS were more related to progression of the disease instead of the development of tolerance to stimulation [53] .
Essential tremor is a bilateral disease presenting with tremors in both arms and it affects the activities of daily living. Therefore, bilateral implantations of thalamic leads will likely be more beneficial than unilateral implantation for patients. However, since bilateral DBS is frequently associated with stimulation-induced dysarthria and balance impairment, unilateral DBS with a lower side-effect profile is now preferred by many centers. Interestingly there are several reports that have found control of ipsilateral arm tremors with unilateral DBS [5] , [84] . Thus, many DBS centers, including ours, tend to offer unilateral implantation of a DBS lead as the safe initial step and stage a second lead only if indicated, requested by the patient, considered safe after an interdisciplinary evaluation.
C. Dystonia
In 2003, the FDA approved the Medtronic Activa system for DBS under a humanitarian device exemption in primary generalized and segmental dystonia. Since that time, many blinded controlled studies including two large European multicenter randomized controlled studies, have been conducted that have revealed improvements. Unfortunately, the clinical improvements seen with globus pallidus DBS fall in a wide range of 20-75%, and the improvements are often delayed, and sometimes observed delayed at 12-18 months after surgery [24] , [85] . Many centers have reported long-term benefits with bilateral globus pallidus internus DBS with improvement sustained for up to 10 years after surgery. One interesting feature related to bilateral globus pallidus DBS is that the benefits may in some cases be sustained, even when the DBS is stopped for days [86] . This has been hypothesized to occur as an effect related to the chronic plasticity induced after long-term stimulation, which can facilitate the abnormal motor patterns required to change into normal motor programs [87] . No clear predictors for clinical outcomes have been identified except for long disease duration and a fixed dystonia-related deformity. Some researchers have proposed that the underlying genetic status, such as the presence of DYT1 gene, plays a significant role in predicting a better outcome, although other studies show conflicting data [24] .
Primary cervical dystonia in which only neck muscles are involved, are usually treated with botulinum toxin injections, however in refractory patients, DBS of the globus pallidus internus may be recommended. In addition to the efficacy in primary dystonia, globus pallidus internus DBS has shown encouraging results in myoclonus-dystonia [88] and tardive dystonia [89] . Benefits in these patients develop rapidly and may be sustained for up to 8 years [85] . Recently, the subthalamic nucleus has gained enthusiasm as a target of choice for primary dystonia. This primarily stemmed from complications that were related to chronic globus pallidus externus DBS such as Parkinsonism and freezing. Subthalamic nucleus DBS in primary cervical dystonia has shown benefits roughly equivalent to those seen with the globus pallidus internus target, although no head to head comparison has been made.
D. Tourette Syndrome
So far, more than 100 patients worldwide have reportedly undergone DBS. Most studies have shown a 40-70% reduction in motor tics at one-year follow-up [27] . The majority of these studies have been open label small series but there are increasing reports of randomized controlled studies that have found promising clinical outcomes and there is a large international registry to record specific details.
One problem with DBS in Tourette syndrome is that there is no clear consensus on the optimal brain target. At least half a dozen targets have been explored so far including the medial thalamus (e.g., centromedian nucleus-parafascicular complex [CM-Pf]) [26] , globus pallidus internus, [90] , [91] , the anterior limb of internal capsule/ nucleus accumbens (ALIC/NAc) [92] , [93] , the globus pallidus externus [94] , and the subthalamic nucleus [95] . Among these, the CM-Pf that has a significant limbic role has been the most commonly used target with over 70 cases performed. Some investigators favor a motor target (globus pallidus internus postero-ventral segment) to address tics and the self-injurious motor tic. Further, some experts prefer the anteromedial globus pallidus as the target for the behavioral features and to suppress the urge to tic [27] . Regardless of the target chosen, the effectiveness of DBS with both globus pallidus and CM-Pf appears to be roughly equivalent when examining existing data. While the results with these two targets are comparable, stimulation of ALIC/NAc, which is also a limbic target, has not shown consistent benefits. In a small series of four patients where ALIC/NAc was pursued in conjunction with thalamic DBS, only one out of these three patients reported a clinical improvement [96] . We await data from the International Tourette Association of America database to inform the field.
VII. ADVANCES IN DEVICE, TECHNIQUES, AND PROGRAMMING
Since standard monopolar or double monopolar stimulation may induce unwanted side effects, many of the current FDAapproved IPGs, such as Medtronics "PC" or "RC" brands have the capacity for novel interleaving modes of stimulation. In this mode of stimulation, two contacts on the quadripolar DBS lead are alternately and independently stimulated with voltages and pulse widths, but the frequency is kept the same. This mode of stimulation may be labor intensive; however different energies can be directed to adjacent anatomical structures and the risks of side effects are potentially minimized [97] . A number of smallscale clinical studies have shown efficacy of the interleaving mode of stimulation for subthalamic nucleus in Parkinson's disease [96] , globus pallidus internus in dystonia [98] , in the STN, and the ventrolateral thalamus in a patient with both Parkinson's disease and essential tremor [99] . [100] . There are a growing number of studies investigating whether changing the patterns of pulse sequences or shapes of stimulus waveform can improve the way we deliver DBS. [101] , [102] .
While the experience with DBS continues to grow, the side effects arising from unwanted stimulation of neighboring structures are becoming increasingly recognized. A novel DBS device marketed by Boston Scientific, called "Vercise" has been launched that combines many of the recent DBS technologies to address some of these issues. Each DBS lead has eight contacts spanning a length of 15.5 mm (see Fig. 2 ). Every contact is 1.5 mm in length, there is 0.5-mm spacing between contacts and the DBS lead is connected to the IPG with a DBS extension that is 55 cm in length. These contacts can simultaneously be stimulated with a constant current and can be controlled independently. Such advanced capabilities of independent current fractionation designed for a more precise stimulation has been referred to as "multiple independent current control" [103] . The Vercise system electrodes are not MRI compatible; but the electrical field of stimulation can be shaped to map the desired anatomical target (discussed later). This device is capable of delivering constant current, and the stimulation settings are flexible with a wider range of capabilities. For example, the stimulation pulse width can be lowered to below 60 μs [104] , and the stimulation frequency can be lowered to the order of 10 Hz, which is not possible with standard devices. The impulse generator (IPG) associated with the Boston Scientific system has a smaller size, is rechargeable with a portable radiofrequency, transcutaneous charging unit, the recharging system is cordless, and the battery life is claimed to last 20-25 years though this will require clinical testing. Rechargeable IPGs reduce the number of battery replacements, which expose the patients to the risk of infection. In a recently concluded multicenter clinical trial (VANTAGE trial) of 40 Parkinson's disease patients recruited from European centers, the overall improvements in motor function, quality of life, and the reduction in use of dopaminergic drugs was comparable to that seen with previous clinical trials using the conventional DBS [105] . Importantly, the frequency and severity of stimulation-induced side-effects seen with subthalamic nucleus DBS in Parkinson's disease were also found to be similar. Similar to the Vercise system, the St Jude system (MN, USA) has a capability of delivering constant current and results from large clinical trial in Parkinson's disease was published recently [77] .
Another consideration important for minimization of side effects is related to the shape of the electrical field. Although the standard DBS electrode has a spherical-shaped electrical field, the brain targets located deep inside the brain do not have a spherical 3-D configuration. Newer DBS designs permit the steering of the electrical field to conform to the needs of the individual patient [106] . Thus, the electrical stimulation can be shaped to the desired target and theoretically avoid unnecessary stimulation of the adjacent structures [107] . Some designs have a lead with electrode contacts that are split in two, three, or even four parts along the circumference of the electrode, with each part being stimulated in a selective and predetermined direction. Conceptually, when stimulating the subthalamic nucleus, current is desired to be steered medially instead of stimulating the laterally located internal capsule. Similarly, in DBS of globus pallidus internus DBS patients, current is desired be steered away from the medially located internal capsule. Two such examples of DBS leads with directional electrode design underwent testing in clinical populations. The first example is the "Direct STIM" lead (Aleva Neurotherapeutics, Switzerland), which has four rings on the lead. Each ring has three electrodes, which are oriented independently to deliver currents in three different directions (see Fig. 2 ). The other design for DBS lead is known as the "SureStim" lead, manufactured originally by Sapiens Company in Netherlands, recently acquired by Medtronic. In this lead design, there are 32 contacts distributed throughout the circumference of the lead (see Fig. 2 ). The design allows a group of contacts to be stimulated simultaneously to steer a particular shape of an electrical field in a particular direction [108] .
A. Advanced Imaging
Many academic DBS centers use 3-T MRI for better identification of smaller deep nuclei such as the subthalamic nucleus or the zona incerta [109] . In the next few years, there is likely going to be an immense change in the procedures that will be followed for brain targeting. With availability of high resolution (7 T) MRI, it will become possible to improve on precisely targeting for the specific parts of a nucleus [110] . Diffusion tensor imaging will enable visualization of the white matter tracts that are close to the active DBS contact, and likely will contribute a deeper insight into DBS mechanisms. This approach along with fMRI preoperatively has gained increasing momentum. For example, the medial forebrain bundle connecting the nucleus accumbens and the prefrontal cortex can be targeted for the treatment of depression and this area can be well visualized with diffusion tensor imaging [111] . In one study of Parkinson's disease patients, the relationship between the white matter tracts surrounding the subthalamic nucleus and the volume of tissue activated with the active contacts of the DBS lead were examined to gain a better understanding of neural networks. This study found the clinically effective contact in the subthalamic nucleus is actually located closer to the dentate-rubro-thalamic tract [112] . Another example is the lateral boundary of the thalamus, which is better identified with this imaging technique, and therefore, placement of a DBS lead into the internal capsule (or too close to capsule) is potentially avoided. Since we are able to delineate anatomical structures better, we can now pursue DBS of somatosensory fibers as a possible treatment for diseases such as chronic pain, and we may be able to refine targets in other diseases [109] .
In addition to structural MRI, functional imaging has undergone many useful advances in recent years. It is known that DBS effects spread beyond the targeted anatomical brain region to affect the connected brain structures. With resting state functional MRI, connectivity within the entire network of targeted brain structures can be easily visualized. Functional connectivity magnetic resonance imaging examines the network related effects. The acquired MRI sequences are low energy and, therefore, are likely safe in patients with DBS. Since the therapeutic benefits of DBS in essential tremor are not related to isolated stimulation of the ventral intermedius nucleus but also to the white matter tracts (dentatorubrothalamic tract) traversing the nucleus and the neighboring regions. There is a growing interest in applying DBS therapy personalized to meet patient needs, for example, patient-specific tractography-activation models enable visualization of white matter tracts activated by the implanted DBS electrode.
B. Closed Loop and Adaptive Stimulation
Standard DBS practice includes stimulation of targeted structures on a continuous basis, except for essential tremor patients where the battery may be frequently switched off during sleep. Turning off the battery increases the neurostimulator life and potentially may avoid tolerance to stimulation effects though this has never been shown clearly by data. In Parkinson's disease, DBS is typically kept on the entire day with the hope that even when dopaminergic medications are less efficiently functioning, symptoms can still be smoothly controlled. There are times when dopaminergic medications provide a good ON and there are times when patients are completely dependent on DBS effects. However, there are also arguments to not use chronic continuous DBS. There is an increasing realization that even with chronic continuous DBS; symptoms show fluctuation even though they are not as distinct as they are before the surgery. Another argument against the use of chronic continuous DBS is that movement disorders are dynamic conditions and use of continuous DBS may result in unwanted side effects [108] .
In Parkinson's disease, beta activity has been proposed to be a reasonable physiological biomarker for an akinetic rigid state. In a study of local field potential recordings, a prominent beta-band oscillation was recorded from the subthalamic nucleus during the times when medications were not working (e.g., off-medication conditions). These oscillations were replaced by gamma-band oscillations when patients received dopaminergic medications and they also regained mobility [114] . Similarly, in Tourette syndrome, where there is a clear sensory urge prior to involuntary tics, DBS activation (on demand) upon detection of sensory potentials may have better outcomes [114] , [115] . These concepts have led to the birth of "closed-loop" or "adaptive" stimulation in the field of DBS. In closed-loop system, there are sensors within the electrodes that monitor the electrical signals that are of relevance to clinical symptoms and the system is triggered "as needed." So far, the clinical results in small clinical cohorts with continuous and adaptive modes of stimulation have both been comparable. In Parkinson's disease, patients undergoing subthalamic nucleus DBS, stimulation was delivered at an individual's gamma-band frequency, which was extracted from the local field potentials recorded during voluntary movements [114] , [116] . The investigators recorded the physiological activity with leads externalized in the immediate post-operative period. The clinical outcomes in this cohort were comparable to those observed with standard stimulation. The same novel concepts of "on demand" stimulation were successfully tested in Tourette syndrome patients with thalamic DBS [117] . All of these studies were primarily based on physiological activity recorded with externalized leads in the immediate postoperative period. With the newer Medtronic Activa PC+S device and the Neuropace device, it is possible to record local field potentials even after internalization of the hardware. We are currently conducting a study on medication refractory Tourette syndrome where the DBS leads of the Activa PC+S device are implanted into the CM-Pf nucleus of the thalamus. There are also cortical electrocorticography (ECOG) strips (RESUME II) placed over the prefrontal cortex to record the cortical potentials. In this system, the electrical signal that corresponds to the tic is recorded from the depth electrodes and the ECOG strip. Stimulation currents are then be adapted according to the local field potential.
With the "closed-loop" system, we can potentially control the time of stimulation and intensity of stimulation. The battery life is longer and the risk of stimulation-induced side effects is reduced. Furthermore, innovations in "closed-loop systems" facilitate a real-time control of stimulation in which, patients wear sensors on the body that can communicate wirelessly with an external programmer. The external programmer in turn communicates with a computer for digital analysis of these signals to implement an appropriate response signal. The main limitation of "on demand" stimulation is inability to determine benefits of adaptive stimulation that it is possible to be achieved on a chronic basis.
VIII. SUMMARY
DBS is a well-established treatment for Parkinson's disease, essential tremor, and dystonia. The number of clinical indications for DBS has continued to grow. DBS is emerging as a potential option for Tourette syndrome, chronic pain, Alzheimer's disease, and epilepsy. The ultimate clinical outcome with DBS is dependent on a complex interplay of numerous factors. A careful clinical selection of subjects through a systematic interdisciplinary evaluation, an accurate imaging-based identification of a brain target, a precise placement of an electrode and using programming parameters that provide the best outcome and least side effects are the keys to successful DBS. The future of this therapy is bright, exciting and is rapidly moving with many technological leaps on the horizon. The novel lead and battery designs are now much better equipped to minimize unwanted side effects. The advanced MRI technology has a potential to substantially improve the accuracy of targeting. These engineering advances have begun to gain proof-of-concept evidence in clinical experiments. Lessons learned from clinical experience along with technological innovations will contribute toward propelling the DBS field forward. However, much remains to be done and these efforts will not be possible without fostering an effective partnership between clinicians, neuroscientists, and especially engineers.
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